ArcticZymes Technologies ASA (OSL:AZT)
kr 13.4 -0.06 (-0.45%) Market Cap: 684.36 Mil Enterprise Value: 451.17 Mil PE Ratio: 167.50 PB Ratio: 2.15 GF Score: 69/100

Q4 2019 Biotec Pharmacon ASA Earnings Call Transcript

Jan 30, 2020 / 07:30AM GMT
Release Date Price: kr7.8 (+21.88%)
Jethro Holter
Biotec Pharmacon ASA - Interim CEO

Okay. Welcome to the Q4 presentation. I'm Jethro Holter, the interim CEO, and I'm joined here today by Børge Sørvoll, who is our CFO. And Børge will share the presentation with me today. Just having a problem with the slides here. There we go. Now it's working.

So the agenda today is what I want to do is we're going to start off recapping the new strategic direction. This is what we presented at the Investor Update Meeting on 10th of December. We will then look at the highlights. We will look at the Q4 achievements and then what we delivered in 2019. We'll then look at the ArcticZymes business, Biotec BetaGlucans. Børge will then take you through the Q4 financials, and then we'll look at the outlook to see what to expect for 2020.

So in terms of the strategy, the new strategic direction, as mentioned, we had an Investors Update Meeting on the 10th of December, and we sort of outlined where we're going to go in the future. I'm going to touch base on the key aspects of that meeting.

For the company, we have one goal moving

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot